Detail

TA-NIC

Description

Name: TA-NIC
Type: biotech
Groups: investigational
Indication: Investigated for use/treatment in tobacco dependence.
Accession Number: DB05445 ( DB05445)
Description: TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. TA-NIC is an immunotherapeutic vaccine similar in concept to TA-CD, designed to raise anti-nicotine antibodies. The antibodies bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain and thus reducing the positive reinforcement and addiction associated with nicotine and cigarette smoking. It is expected that the reduction of the positive reinforcement will in turn reduce the desire to smoke or use other tobacco products.
Structure:
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients

Categories
  • No Category

Pharmacology

Indication: Investigated for use/treatment in tobacco dependence.
Pharmacodynamics: Not Available
Mechanism of action: Reduces nicotine entry into the brain and thus the positive reinforcement associated with smoking.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: TA-NIC consists of nicotine conjugated to the carrier protein rCTB and an aluminium adjuvant.
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Appears to be well-tolerated.
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Not Available

Packagers:
  • Not Available

Dosage forms
FormRouteStrength

Prices
Unit descriptionCostUnit

Patents
CountryPatent NumberApprovedExpires (estimated)

Interactions

Drug Interactions
DrugInteraction

Food Interactions:
  • Not Available

Taxonomy

Kingdom: Organic Compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Not Available

substituent:
  • Not Available

References

Synthesis Reference: Not Available
General Reference: # Goniewicz ML, Koszowski B, Czogala J, Zymelka A: [New prospects of nicotine dependence treatment--vaccines] Przegl Lek. 2006;63(10):1114-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17288232 # Cerny T: Anti-nicotine vaccination: where are we? Recent Results Cancer Res. 2005;166:167-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15648190 # Trial watch: Xenova's TA-NIC vaccine shows promise. Expert Rev Vaccines. 2004 Aug;3(4):386. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15270640 # Hagenbuch B, Meier PJ: Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994 Mar;93(3):1326-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8132774
External Links:
ResourceLink

ATC Codes:
  • Not Available

AHFS Codes:
  • Not Available

MSDS: Download
SiteLock

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

CONTACT US

The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

Sending
or

Log in with your credentials

Forgot your details?